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1. Introduction
With  a  growing  older  population,  cardiovascular  diseases  are  becoming  an  increasing
economic and social  burden in Western societies.  Cardiovascular calcification is  a  major
characteristic  of  chronic inflammatory disorders — such as chronic renal  disease (CRD),
type  2  diabetes  (T2D),  atherosclerosis  and  calcific  aortic  valve  disease  (CAVD)  —  that
associate  with  significant  morbidity  and  mortality.  Cardiovascular  calcification  also
associates with osteoporosis in humans and animal models [1, 2] — the so-called “calcifica‐
tion paradox” [3]. The concept that similar pathways control both bone remodeling and
vascular calcification is currently widely accepted, but the precise mechanisms of calcifica‐
tion  remain  largely  unknown.  Osteogenic  transition  of  vascular  smooth  muscle  cells
(SMCs),  valvular  interstitial  cells  (VIC)  or  stem cells  is  induced by bone morphogenetic
proteins, inflammation, oxidative stress, or high phosphate levels,  and leads to a unique
molecular  pattern marked by osteogenic  transcription factors  [4].  Loss  of  mineralization
inhibitors,  such  as  matrix  γ-carboxyglutamic  acid  Gla  protein  (MGP)  and fetuin-A also
contribute to cardiovascular calcification. The physiological balance between induction and
inhibition of calcification becomes dysregulated in CRD, T2D, atherosclerosis, and CAVD.
Consequently,  calcification  may  occur  at  several  sites  in  the  cardiovascular  system,
including the intima and media of vessels and cardiac valves [3].
The central role of miRNAs as fine-tune regulators in the cardiovascular system and bone
biology has gained acceptance and has raised the possibility for novel therapeutic targets.
Circulating miRNAs have been proposed as biomarkers for a wide range of cardiovascu‐
lar  diseases,  but  knowledge  of  miRNA  biology  in  cardiovascular  calcification  is  very
limited.
© 2013 Goettsch and Aikawa; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Micro-RNA biology: Biosynthesis and function
Micro-RNAs (miRNAs) are a large class of evolutionarily conserved, small, endogenous, non-
coding RNAs serving as essential post-transcriptional modulators of gene expression [5].
miRNAs regulate biological processes by binding to mRNA 3’-untranslated region (UTR)
sequences to attenuate protein synthesis or messenger RNA (mRNA) stability [6]. Acting as
genetic switches or fine-tuners, miRNAs are key regulators of diverse biological and patho‐
logical processes, including development, organogenesis, apoptosis, and cell proliferation and
differentiation. miRNA dysregulation often results in impaired cellular function and disease
progression. It has been estimated that the whole human genome encodes for about 1000
miRNAs which may be located within introns of coding or non-coding genes, within host
exons or within intergenic regions [7].
miRNA biogenesis is shown in Figure 1. The transcription process is mediated by the RNA-
polymerase II that produces long precursor RNAs known as “primary miRNA” (pri-miRNA)
with a typical hairpin morphology [8]. A nuclear endonuclease, called DROSHA, then crops
the distal stem portion of pri-RNA obtaining shorter chains (pre-miRNA) [9]. Pre-miRNA is
transported to the cytoplasm by the nuclear receptor Exportin-5 [10] and processed by DICER,
an RNase III, to short double-stranded RNA sequence containing the miRNA and the ‘star
strand’ (miRNA*). miRNA* is degraded after stripping the miRNA strand to obtain mature
miRNA [11]. Mature miRNA interact with proteins like Argonaute endonuclease (Arg 2), in
order to form the RNA-induced silencing complex (RICS), which directs mature miRNA
towards the targeted mRNA and bind on their 3’ untranslated region (UTR) [6].
A single miRNA may modulate hundreds of miRNAs, and one mRNA has multiple predicted
binding sites for miRNAs in their 3’UTR. Furthermore, after cleavage of a target mRNA,
miRNAs are not Destroyed; so they may recognise and modulate other mRNAs [5, 12].
3. miRNAs and cardiovascular disease
Cardiovascular calcification is an independent risk factor for cardiovascular morbidity and
mortality. Several risk factors can accelerate atherosclerosis and cardiovascular calcification,
including age, hypercholesterolemia, metabolic syndrome, CRD, and T2D. Cardiovascular
calcification can be distinguished by location — as intimal (atherosclerotic) , medial (CRD,
T2D), or valvular [3]. Atherosclerotic calcification occurs as a part of atherogenic progress in
the vessel intima. Small hydroxyapatite mineral crystals (microcalcification) can be visualized
in early lesions [13]. Medial calcification occurs primarily in association with CRD and T2D,
independently of hypercholesterolemia. Aortic valve calcification leads to impaired move‐
ment of aortic valve leaflets, and causes valve dysfunction [2]. All three processes shared risk
factors and etiological factors, including inflammation and oxidative stress.
The identification of circulating miRNA as a novel biomarker in various diseases is a growing
area of research investigation. Many pioneering studies describe specific miRNA patterns in
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cardiovascular diseases. The first study reporting circulating miRNAs in patients with
atherosclerosis was published in 2010, demonstrating a reduction of circulating vascular- and
inflammation-associated miRNAs (miR-126, miR-17, miR-92a, miR-155) in patients with
coronary artery disease (CAD) [14]. In addition, tissue levels of miRNAs were investigated.
Here we summarize and discuss the current knowledge on circulating and tissue miRNAs in
diseases associated with cardiovascular calcification (Tables 1 and 2).
3.1. miRNAs in coronary artery disease
Studies  about  miRNA  expression  in  calcified  vessels  are  rare.  Li  et  al.  analyzed  the
expression of miRNAs in patients with peripheral artery disease (arteriosclerosis obliter‐
ans),  characterized by fibrosis  of  the tunica intima and calcification of  the tunica media
[15].  miR-21,  miR-130a,  miR-27b,  let-7f,  and miR-210  were  significantly  increased,  while
miR-221 and miR-222 were decreased in the sclerotic intima, compared to normal vessels
[15].  Higher  levels  of  miR-21  and  miR-210  were  confirmed  in  a  study  that  compared
atherosclerotic with non-atherosclerotic left internal thoracic arteries [16]. In addition, the
expression of miR-34a, miR-146a, miR146b-5p, and miR-210 increased more than 4-fold in
atherosclerotic arteries. Several predicted targets were downregulated [16]. Another study
found  a  different  miRNA  pattern  using  plaque  material  from  the  carotid  artery,  com‐
Figure 1. Schematic overview of miRNA biogenesis.
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pared  with  the  arteria  mammaria  interna  as  control  tissue  [17].  The  healthy  vessel  ex‐
pressed  higher  levels  of  miR-520b  and  miR-105,  whereas  miR-10b,  miR-218,  miR-30e,
miR-26b, and miR-125a were predominantly expressed in atherosclerotic plaque [17]. The
investigators  in  both  studies,  however,  did  not  examine  miRNAs  in  calcified  lesions.
Microcalcification  is  thought  to  cause  plaque  rupture  [18,  19].  Destabilized  human pla‐
ques  are  characterized  by  a  specific  miRNA expression  profile  (high  levels  of  miR-100,
miR-127,  miR-145,  miR-133a,  miR-133b).  Target  genes  of  these  miRNAs  (Nox1,  MMP9,
CD40) may play a role in vascular calcification [7]. Thus, miRNAs could participate in the
formation  of  hydroxyapatite  crystals,  and thereby  have  an  important  role  in  regulating
atherosclerotic plaque toward unstable phenotypes and rupture [20].
Fichtlscherer et al. authored the first study investigating circulating miRNA in CAD [14].
Plasma levels of miR-17, miR-92a, miR-126, miR-145, and miR-155 were reduced in CAD
compared to healthy controls, whereas miR-133a and miR-208a were increased [14]. Another
study demonstrated a positive correlation of plasma miR-122 and miR-370 levels with the
presence and severity of CAD [21]. Both miRNAs were significantly increased in hyperlipi‐
demia patients, compared to controls [21]. Increased levels of miR-27b, miR-130a, and miR-210
were observed in the serum of arteriosclerosis obliterans patients [15].
Comparison of published studies is challenging mainly because of the different sources of
circulating miRNAs, which include serum, whole blood, PBMCs, EPCs, and platelets (Table
1). The miRNA profiles obtained from the different studies, therefore, are often not the same.
In this context, a recent report suggested the necessity of careful selection for reference miRNAs
by showing that hemolysis may significantly affect the levels of plasma miRNAs previously
used as controls [22].
Polymorphisms in the 3’UTR may alter miRNA binding, leading to post-transcriptional
dysregulation of the target gene and aberrant protein level. Functional single-nucleotide
polymorphisms (SNPs) of miRNA-binding sites associate with the risk of cardiovascular
disease. Wu et al. discovered a SNP in the miR-149 binding site of the 5,10-methylenetetrahy‐
drofolate reductase (MTHFR) gene that associated with increased risk for CAD [23]. Further‐
more, a larger study in a Chinese population of 956 CAD patients and 620 controls revealed
that a SNP in the binding sites for miR-196a2 and miR-499 associated with the occurrence and
prognosis of CAD [24].
3.2. miRNAs in diabetes and chronic renal disease (CRD)
T2D is a major risk factor for cardiovascular disease. Zampetaki et al. identified a plasma
miRNA signature for T2D that includes reduced levels of miR-223, miR-15, miR-20b, miR-21,
miR-24, miR-29b, miR-126, miR-150, miR-191, miR-197, miR-320, and miR-486, and elevated
levels of miR-28-3p [33]. Reduced miR-126 levels antedated diabetes manifestation, and might
explain the impaired peripheral angiogenic signaling in patients with T2D. Reduction of
circulating miR-21 and miR-126 was confirmed by Meng et al., who also found a decrease of
miR-27a,b and miR-130a in T2D patients [35]. Another study demonstrated mostly elevated
miRNA levels (miR-9, miR-29a, miR-30d, miR-34a, miR-124a, miR-146a, and miR-375) in
serum from T2D patients, compared with pre-diabetic and/or normal glucose tolerance
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conditions [36]. In contrast, reduced miR-146a levels in PMBCs from Asian Indian T2D patients
associated with insulin resistance, poor glycemic control, and several proinflammatory
cytokine genes [34]. miR-146a participates in the transcriptional circuitry regulating fibronec‐
tin in T2D animals.[39].
The high incidence of cardiovascular complications in patients with CRD is partly explained
by more aggressive development of atherosclerotic lesions and accelerated calcification [40].
To our knowledge, only one study reports circulating miRNA in patients with CRD. Neal et
miRNA Disease Source Finding Referencenumber
miR-17, -21, -20a, -22a, -27a, -92a, -126, -145, -155, -221,
-130a, -208b, let-7d
miR-133a, -208a
CAD Serum
Decreased
[14]
Increased
miR-146a/b CAD PBMC Increased [25]
miR-34a CAD EPC Increased [26]
miR-221, -222 CAD EPC Increased [27]
miR-135a, -147 CAD PBMC Decreased [28]
miR-140, -182 CAD Whole blood Decreased [29]
miR-122, -370 CAD Plasma Increased [21]
miR-181a CAD Monocytes Decreased [30]
Let-7i CAD Monocytes Decreased [31]
miR-340, -624 CAD Platelets Increased [32]
miR-20b, -21, -24, -29b, -15a, -126, -150, -191, -197, -223,
-320, -486
miR-28-3p
T2D Plasma
Decreased
[33]
Increased
miR-146a T2D PBMC Decreased [34]
miR-21, -27a, b, -126, -130a T2D EPC Decreased [35]
miR-9, -29a, -30d, -34a, -124a, -146a, -375 T2D Serum Increased [36]
miR-16, -21, -155, -210, -638 CRD Plasma Decreased [37]
miR-188-5p, -135*, -323-3p, -509-3p, -520-3p, -572, -573,
629*, -632
miR-24, -106a, -191, -218, -222, -223, -342-3p, -412, let-7p
HC HDL
Decreased
[38]
Increased
miR-21, -27b, -130a, -210 AO Serum Increased [15]
CRD, chronic renal disease; T2D, type 2 diabetes; CAD, coronary artery disease; AS, aortic stenosis; HC, familial hyper‐
cholesterolemia; AO, arteriosclerosis obliterans; PBMC, peripheral blood mononuclear cell; EPC, endothelial progenitor
cell; HDL, high-density lipoprotein.
Table 1. Circulating miRNA in diseases associated with vascular calcification.
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al. found that plasma levels of total and specific miRNAs (miR-16, miR-21, miR-155, miR-210,
and miR-638) are reduced in CRD patients, compared to patients with normal renal function
[37]. A strong correlation exists between detected circulating miRNAs and estimated glomer‐
ular filtration rate [37]. Interestingly, miR-638 was the only miRNA that showed a differential
urine excretion in CRD patients [37]. Transforming growth factor beta (TGF-β), a pro-fibrotic
key mediator of CRD, reduces levels of miR-192 [41] and miR-29a [42] and increases miR-377
levels [43] in vitro and in vivo, thereby promoting the expression of extracellular matrix
components.
3.3. miRNAs and aortic valve disease
Aortic stenosis (AS) is typically caused by calcific aortic valve disease. To our knowledge, no
study to date describes a specific miRNA signature in the circulation of patients with AS.
Nigam et al. identified a miRNA pattern specific to AS using tissue from whole bicuspid valves
and linking them to calcification-related genes, such as Smad1/3, Runx2, and BMP2 [44].
miR-26a, miR-30b, and miR-195 were decreased in the aortic valves of patients requiring
replacement due to AS, compared to those requiring replacement due to aortic insufficiency
[44]. Another group compared bicuspid with tricuspid aortic valve leaflets by miRNA
microarray, and found a number of modulated miRNAs [45]. Particularly, miR-141 had the
most dramatic change, showing a 14.5-fold decrease in the bicuspid versus tricuspid valve
tissue, while the levels of calcification were comparable between the two groups.
3.4. Similar miRNA profiles may represent common miRNAs in diseases associated with
cardiovascular calcification
Our detailed investigation using currently published literature revealed common circulat‐
ing  miRNAs  in  diseases  associated  with  vascular  calcification.  Seven  miRNAs  (miR-21,
miR-27,  miR-34a,  miR-126,  miR-146a,  miR-155,  and  miR210)  were  useful  biomarkers  in
atherosclerosis, T2D, and/or CRD, and only miR-21 was common among all three diseas‐
es [14, 33, 37] (Table 3).
Atherosclerotic arteries [16] and sclerotic intima from lower-extremity vessels [15] expressed
higher miR-21 levels than did healthy vessels. Circulating levels of miR-21 in atherosclerosis,
T2D, and/or CRD were reduced [14, 33, 37]. The reason for this discrepancy is unknown, and
requires further investigation.
miR-146a is an inflammation-related miRNA, implicated in atherosclerosis and osteoclasto‐
genesis [46]. Circulating miR-146a is increased in CAD patients [25] and T2D [36]. In addition,
miR-146a was more highly expressed in atherosclerotic arteries in an animal model [16], and
associated with CRD in vivo [47]. miR-155, another inflammation-associated miRNA, is
decreased in CAD [14] and CRD [37]. Deficiency of miR155 enhanced atherosclerotic plaque
development and decreased plaque stability [48], suggesting that it acts as an anti-inflamma‐
tory and atheroprotective miRNA. miR-155 is also highly expressed in endothelial cells (ECs)
and SMCs, where it targets angiotensin-II receptor [49]. The renin–angiotensin system
participates in cardiovascular calcification [50, 51]. Angiotensin-receptor blockade can inhibit
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arterial calcification by disrupting vascular osteogenesis in vivo [52]. In addition, an observa‐
tional study showed reduced progression of AV disease in patients taking angiotensin-
converting enzyme inhibitors [53]. Furthermore, miR-155 represses osteoblastogenesis by
targeting Smad proteins [54]. Thus, high expression of miR-155 may prevent cardiovascular
miRNA Disease Tissue type Finding Referencenumber
miR-21, -34a, -146a,
-146b-5p, -210 CAD
Atherosclerotic
arteries Increased [16]
miR-105, -520b
miR-10b, -26b, -30e, -125a, -218, CAD
Atherosclerotic
carotid artery
Decreased
[17]
Increased
miR-100, -127, -133a,b
-145 CAD Destabilized plaque Increased [20]
miR-221, -222
miR-21, -27b, -210, -130a, let-7f AO
Sclerotic intima from
lower extremities
vessels
Decreased
[15]
Increased
miR-22, -27a, -141, -124,
-125b, -185, -187, -194,
-211, -330, -370, -449,
-486, -551, -564, -575, -585, -622, -637, -648,
-1202,
-1282, -1469, -1908, -1972
miR-30e, -32, -145, -151, -152, -190, -373, -768
AS Bicuspid aortic valve
Decreased
[45]
Increased
miR-26a, -30b, -195 AS Whole bicuspidvalves Decreased [44]
CAD, coronary artery disease; AS, aortic stenosis; AO, arteriosclerosis obliterans.
Table 2. miRNAs expressed in human calcified tissue.
CAD T2D CRD
miR-21 ↓ miR-21 ↓ miR-21 ↓
miR-27 ↓ miR-27 ↓
miR-34a ↑ miR-34a ↑
miR-126 ↓ miR-126 ↓
miR-155 ↓ miR-155 ↓
CRD, chronic renal disease; T2D, type 2 diabetes; CAD, coronary artery disease
Table 3. Common circulating miRNA in diseases associated with vascular calcification.
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calcification by inhibiting the BMP signalling pathway or the renin–angiotensin system,
making it a promising anti-calcification therapeutic target.
In summary, a set of circulating miRNAs (consisting of miR-21, miR-27, miR-34a, miR-126,
miR-146a, miR-155, and miR-210) is dysregulated in various pro-inflammatory diseases and
may represent a miRNA signature for cardiovascular calcification. Of note, systemic and local
inflammation paradoxically affects cardiovascular calcification and bone loss, which supports
the concept of inflammation-dependent cardiovascular calcification previously proposed by
our group and others [13, 40, 55-57].
4. miRNA and osteogenesis in the vascular wall
Cardiovascular calcification is an active, cell-regulated process. Various studies provide
evidence of phenotypic transition or transition/dedifferentiation of mature SMCs or VICs into
an osteogenic phenotype — a key feature in cardiovascular calcification. In medial calcification,
SMCs undergo dedifferentiation from a contractile to a pro-atherogenic synthestic phenotype,
lose the expression of their marker genes, acquire osteogenic markers, and deposit a mineral‐
ized bone-like matrix. In valvular calcification, VICs can undergo the transition to osteoblast-
like bone-forming cells [58]. Recently, a novel concept emerged of circulating cells harboring
osteogenic potential that can home to atherosclerotic lesions and contribute to intimal calcifi‐
cation [59, 60]. Comparing the sources of cells that contribute to atherosclerotic intimal
calcification revealed that SMCs are the major contributors that reprogram its lineage towards
osteochondrogenesis/blastogenesis; circulating bone marrow-derived cells, however, also
contribute to early osteochondrogenic differentiation in atherosclerotic vessels [61]. The master
transcription factors, including Runx2/Cbfa1, Msx2, and Osterix, designate cells for osteoblast
lineages through the induction of downstream genes such as alkaline phosphatase, osteopon‐
tin, and osteocalcin. Here we summarize miRNAs involved in SMC differentiation, as well as
in osteogenesis, with targets involved in cardiovascular calcification.
The SMC phenotype is dependent on the miR-143/145 cluster [62-64]. Circulating miR-145
levels are reduced in CAD patients [14]. miR-145 is one of the most recognized arterial miRNAs
[65]. Inhibition of miR-143/145 promotes a phenotypic switch to the synthetic, pro-atherogenic
SMC state [62], including the inhibition of SMC marker-like alpha-smooth muscle actin and
smooth muscle myosin heavy chain [66] — both diminished in osteogenic SMCs [67]. miR-145
modulates SMC differentiation by targeting Krüppel-like factor 4 (KLF4) [63]. KLF4 mediates
high phosphate-induced conversion of SMCs into osteogenic cells [68]. Conversely, miR-145-
deficient mice [69] and overexpression of miR-145 [66] both reduce neointima formation in
vascular injury.
Similar to miR-145, miR-133 has a potent inhibitory role on the vascular SMC phenotypic
switch [70]. Runx2, a cell-fate determining osteoblastic transcription factor, is a target of
miR-133 [71]. Runx2 acts as a critical regulator of osteogenic lineage and a modulator of bone-
related genes [72]. Runx2 is essential and sufficient for regulating osteogenesis in SMC and
VIC [73, 74, 75, 76]. Discovered in the bone biology field, a program of miRNAs controls Runx2
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expression to prevent skeletal disorders [77]. Three of these miRNAs (miR-133a, miR-135a,
and miR-218) are altered in cardiovascular diseases associated with vascular calcification [14,
17, 20, 28]. Klotho mutant mice, which display vascular calcification due to hyperphosphate‐
mia and through a Runx2-dependent mechanism [78], show overexpression of miR-135a
(together with miR-762, miR-714, and miR-712) in the aortic media, which causes SMC
calcification by disruption of Ca2+ transporters and increasing intracellular Ca2+ concentrations
[79]. More recently, miR-204, another candidate of the Runx2-cluster, was found to contribute
to SMC calcification in vitro and in vivo [80]. Downstream targets of Runx2 are bone-specific
genes like osteopontin, osterix and osteocalcin, all present in the cardiovascular osteogenic cell
phenotype [2, 81]. We recently demonstrated that miR-125b, which inhibits osteoblast
differentiation [82] regulates the transition of SMCs into osteoblast-like cells partially by
targeting the transcription factor osterix, providing the first miR-dependent mechanism in the
progression of vascular calcification [83]. Additionally, miRNA-processing enzymes —
essential for SMC function [84] — were reduced in calcified SMCs [83].
Another potent regulator of vascular and valvular calcification is the BMP signaling pathway
(reviewed in detail elsewhere [85]). BMP2 and BMP4 are potent osteogenic differentiation
factors detected in calcified valve and atherosclerotic lesions [86-88]. BMPs elicit their effects
through activation of receptor complex composed of type I and type II receptors and activate
receptor-type–dependent and ligand-dependent Smad transcription factors, which modulate
the expression of Runx2 [85]. MiR-26a, miR-135, and miR-155 were previously reported as
Smad-regulating miRNAs related to osteoblastogenesis; they functionally repress osteoblast
differentiation by targeting Smad1 and Smad5, respectively [54]. miR-155 is one of the
circulating miRNAs that is decreased in CAD [14] and CRD [37] (discussed earlier). miR-26a
was repressed in aortic valve leaflets of patients with aortic stenosis, and human aortic valvular
interstitial cells showed decreased mRNA levels of BMP2 and Smad1 when treated with
miR-26a mimic [44]. The same group found lower expression of miR-30b, which targets Smad1
and Smad3. Another group reported deceased miR-141 levels together with increased BMP2
levels in bicuspid versus tricuspid aortic valve leaflets, and showed in vitro that miR-141
represses the VIC response to calcification, in part through BMP2-dependent calcification [45].
Itoh et al. identified miR-141 as a pre-osteoblast differentiation-related miRNA, which
modulated the BMP2-induced pre-osteoblast differentiation by direct translational repression
of Dlx5, a transcription factor for osterix [89].
Activation of canonical wingless-type (WNT) signaling is crucial for osteoblast function [90]
and for the programming of valvular and vascular cells during cardiovascular calcification
[85]. Activation of the Wnt/β-catenin signaling pathway occurs in human calcified aortic valve
stenosis [91], in LDL receptor (LDLR)-deficient mice [92, 93], and in osteogenic SMCs in vitro
[94]. Dickkopf (Dkk)1 is an extracellular antagonist of the canonical Wnt signaling that plays
a crucial role in bone remodeling by binding to and inactivating signaling from LDLR-related
protein 5/6 [95, 96]. Dkk-1 may also play a role in vascular calcification. In CRD patients, Dkk1
serum levels correlated negatively with arterial stiffness [97]. Dkk-1 prevents warfarin-
induced activation of β-catenin, and osteogenic transdifferentiation of SMCs [98] and TNF α-
induced induction of alkaline phosphatase activity [92]. Remarkably, two miRNAs targeting
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bone Dkk-1 (miR-335-5p, miR-29a) increase with age [99, 100] — a risk for cardiovascular
calcification. miR-335-5p directly targets and represses Wnt inhibitor Dkk-1, thereby enhanc‐
ing Wnt signaling and promoting osteoblast differentiation [101]. To date, no publications exist
regarding the role of miR-335-5p in the cardiovascular system. Yet, the age-dependent increase
of miR-335 in rat renal tissue inhibited the expression and function of the enzymes implicated
in oxidative stress defense [99]. Likewise, miR-29a potentiates osteoblastogenesis by modu‐
lating Wnt signaling. Canonical Wnt signaling induces miR-29a expression, which negatively
targets regulators of Wnt signaling, including Dkk-1, sFRP2, Kremen, and osteonectin [102,
103]. miR-29 increased age-dependently in mouse aortic tissue and associated with reduced
extracellular matrix components, such as collagen and elastin [100]. Elastolysis accelerates
arterial and aortic valve calcification [40]. Furthermore, MMP-2, another target of miR-29 [104],
was shown to promote arterial calcification in CRD [105] and valvular calcification [106].
The contribution of osteoclasts to cardiovascular calcification is still controversial [59]. The
observation of osteoclast-like cells in calcified atherosclerotic lesions suggested this bone-
related cell is active in the vessel wall. The evidence was strengthened recently by Sun et al.,
who demonstrated the functional role of SMC-derived Runx2 promoting infiltration of
macrophages into the calcified lesion to form osteoclast-like cells — suggesting that the
development of vascular calcification is coupled with the formation of osteoclast-like cells,
paralleling the bone remodeling process [74]. The receptor activator of the nuclear factor-kappa
B (NF-kappa B) ligand (RANKL)/osteoprotegerin (OPG) system controls proper osteoclasto‐
genesis, and actes as a biomarker for CAD [107, 108]. In silico analysis revealed RANKL as a
target of miR-126 [109], which is decreased in the plasma of CAD [14] and T2D [33] patients.
miR-146a, highly expressed in atherosclerotic arteries [16], inhibits osteoclastogenesis [46]. The
number of tartrate-resistant acid phosphatase-positive multinucleated cells was significantly
reduced by miR-146a in a dose-dependent manner [46]. Furthermore, miR-155, which is
decreased in plasma of CRD [37] and CAD [14] patients, was shown to inhibit osteoclast
function [110].
Taken together, osteogenic processes in both bone and the cardiovascular system are tightly
controlled by miRNAs (Figure 2). Further studies are needed to elucidate whether interplay
of miRNAs could explain the bone-vascular axis “calcification paradox,” or whether they act
independently in the calcifying vessel and bone.
5. Circulating miRNAs as biomarkers and extracellular communicators
miRNAs are present in blood (plasma, platelets, erythrocytes, nucleated blood cells) with high
stability. miRNAs can circulate in extracellular vesicles [111], in a protein complex (Ago2), or
in a lipoprotein complex (HDL) [38], which prevents their degradation. Depending on the size
and type, extracellular vesicles are broadly classified as ectosomes (also called shedding
microvesicles), exosomes, matrix vesicles (MVs), and apoptotic bodies. Ectosomes are large
extracellular vesicles 50-1000 nm in diameter; exosomes are small membranous vesicles of
endocytic origin, 40-100 nm in diameter; MVs are 30-300 nm in diameter, are produced by
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blebbing of the plasma membrane, and can calcify; and apoptotic bodies, 50-5000 nm in
diameter, are released from fragmented apoptotic cells.
The majority of miRNAs are independent of vesicles [111] and co-purify with the Ago2
complex [112, 113]. But in CAD patients, most plasma miRNAs associate with extracellular
vesicles, and only a small amount are found in extracellular vesicle-free plasma [114]. A cell-
type-specific miRNA release and different export systems are implicated, as the miRNA
release pattern within vesicles is different from that associated with Ago2 complexes [112].
Thus, cells can select miRNA and pre-miRNA for controlled cellular release [115, 116]. miRNA
profiles of extracellular vesicles are different from their maternal cell profiles, indicating an
active mechanism of selective miRNA packing from cells into vesicles [114]. We have limited
knowledge about miRNA secretion. Blockade of sphingomyelinase inhibits exosome genera‐
tion and miRNA secretion, and intercellular miRNA transfer implicates a ceramide-dependent
mechanism [117, 118]. Ago2–miRNA complexes may be passively produced by dead cells,
released by live cells, or actively transported though cell-membrane–associated channels or
receptors [119].
Extracellular vesicles use miRNA to mediate intercellular communication over long distances
or on a local tissue level [120]. Endothelial apoptotic bodies can convey miR-126 to athero‐
sclerotic lesions, which demonstrate uniquely paracrine-signaling function for miRNA during
Figure 2. Potential and established miRNAs contributing to osteogenic regulation of vascular calcification.
Bold, established miRNAs in vascular calcification; underlined, dysregulated in cardiovascular disease (circulating or tis‐
sue); gray, predicted miRNA binding sites.
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atherosclerosis [33, 121]. miRNA-containing vesicles can regulate intercellular communication
between ECs and SMCs by selective packing of miR-143/145 in endothelial-derived vesicles,
which are then transported to SMCs to control their phenotype [118].
How miRNAs are taken up by target cells and remain biologically active is still unknown. We
know little about the mechanisms of vesicle-mediated cargo transfer. In physiological condi‐
tions, extracellular vesicles may bind to the membrane proteins of the surface of target cells
through receptor–ligand interaction, resulting in intracellular stimulation of genetic pathways.
They can also fuse with cell–target membranes and release genetic content in a nonselective
manner. Furthermore, vesicles can bind to surface receptors on target cells with endocytotic
internalization by recipient cells, followed by fusion with the membranes, leading to a release
of their content into the cytosol of target cells [122].
A key event in the initiation and promotion of VIC and SMC calcification is the release of
extracellular vesicles [81, 123]. Treatment of SMCs with elevated calcium levels promotes the
production of calcifying vesicles (MVs), and the loss of fetuin-A, an inhibitor of mineral
nucleation [124]. These vesicles act as early nucleation sites for calcification. The phosphati‐
dylserine-membrane complex from SMC-derived and macrophage-derived MVs redistributes
and nucleates hydroxyapatite [125-127]. In addition, hydroxyapatite nanocrystals shed from
vesicles may further promote mineralization via direct effects on SMC phenotype [128].
Insight into the underlying mechanism of selective packing of miRNAs into extracellular
vesicles and selective uptake into the target cell will help increase understanding of the role
of miRNA-containing vesicles in physiological intercellular communication, which may
prevent calcification in the cardiovascular system.
6. miRNAs in the “calcification paradox”
Osteoporosis frequently associates with cardiovascular calcification, and the severity of aortic
calcification associates positively with bone loss [2, 129, 130]. The “calcification paradox” could
be explained by the shared molecular pathways in bone remodeling and cardiovascular
calcification [3]. How these two processes associate with each other and whether osteoporosis
leads to cardiovascular calcification - or whether both disorders just share common risk factors
- is unclear. In this section, we link cardiovascular calcification and bone loss and show
commonalities in the systems’ miRNA pathways/patterns.
Studies of miRNA in patients with bone disease are lacking. A recent clinical study first
reported miRNA as a potential biomarker for postmenopausal osteoporosis. Wang et al.
demonstrated an association of miR-133a levels in circulating monocytes - osteoclast precur‐
sors - with postmenopausal osteoporosis [131]. Women with low bone mineral density showed
higher circulating miR-133a levels [131], but the number of patients per group was small (n=10).
Circulating miR-133a levels were also higher in patients with CAD [14]. Unfortunately, the
study investigating bone mineral density in patients with osteoporosis did not mention
characteristics of the cardiovascular patient population. miR-133a belongs to the Runx2-
targeting miRNA cluster [77].
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Additionally, miR-2861 contributes to osteoporosis in mice and humans by targeting histone
deacethylase 5, and thereby increasing Runx2 [132]. No studies of miR-2861 in the cardiovas‐
cular system have been reported. Patients with rheumatoid arthritis also suffer from vascular
calcification in different vessel beds, in addition to osteoporosis; the pathogenesis includes
pro-inflammatory cytokines and site-specific inflammation (reviewed in detail elsewhere
[133]). miR-146a, a negative regulator of inflammation and osteoclastogenesis, also associates
with rheumatoid arthritis [134]. Similar to patients with CAD, in patients with rheumatoid
arthritis, miR-146a is up-regulated in PBMCs [25].
7. Conclusion and perspectives
In vitro and in vivo studies have established miRNAs as biomarkers focusing on different
aspects and providing circulating miRNA signatures for different diseases. But these circu‐
lating miRNAs may not have biological functions within the cell while circulating — instead,
they act as intercellular communicators, and this communication may be disturbed by calcified
vesicles. More studies are needed to fully exploit this potentially novel mechanism of cardio‐
vascular calcification.
Moreover, miRNA biology is very complex. Multiple miRNAs can target the same gene (e.g.,
Runx2–miRNA cluster), and one miRNA may have several targets. Only a small amount of
these fine-tuned targets may alter biological responses and phenotypes. Understanding the
role of miRNA in vascular calcification may be helpful in considering the paradoxical clinical
observations of the concurrence of cardiovascular calcification and osteoporosis. Despite its
global clinical burden, no medical therapies are available to treat cardiovascular calcification.
Targeting of miRNA represents a novel therapeutic opportunity for treating calcification
disorders. As vascular calcification and bone remodeling share common mechanisms, we have
to understand in greater detail the functions of miRNAs and their association with the
molecular pathogenesis of osteoporosis and vascular/valvular calcification.
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